The advancement in the MEAI-based alcohol substitute beverage program and the initiation of the last pre-clinical study required for a novel-food application submission is a significant step forward for Clearmind Medicine. This progress could positively impact the company's stock price in the short term as it demonstrates ongoing development and potential future revenue streams.